艾吉納斯 AGEN 深 滬
等待開盤 11-26 09:30:00 美东时间
4.38
+0.090
+2.10%
華盛通- 最 高4.48
- 今 開4.29
- 成交量 38.70万股
- 最 低 4.29
- 昨 收 4.29
- 總市值 1.49亿
- 52周最高 7.34
- 市盈率 靜 --
- 換手率 1.14%
- 52周最低 1.38
- 委 比 -27.54%
- 總股本 3400.83万
- 歷史最高 202.5868
- 量 比 1.01
- 振 幅 4.43%
- 歷史最低 1.38
- 每 手 1
- 風險率 1.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Agenus reports Q3 results
Agenus press release (AGEN): Q3 GAAP EPS of $1.94. Revenue of $30.2M (+20.3% Y/Y). More on Agenus Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript Agenus Inc. (AGEN) Virtual Stakeholder Briefing...
11-10 20:37
Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate
Agenus (NASDAQ:AGEN) reported quarterly earnings of $1.94 per share which missed the analyst consensus estimate of $1.98 by 2.02 percent. This is a 162.99 percent increase over losses of $(3.08) per share from the same
11-10 20:32
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Earnings week ahead: DIS, CSCO, OXY, PLUG, B, AMAT, JD, BYND, PSKY, and more
Earnings in the upcoming week will spotlight a diverse lineup across media, technology, energy, aerospace, and consumer sectors. The Walt Disney Company (DIS) and Paramount Skydance (PSKY) will be in ...
11-09 21:16
Insights Ahead: Agenus's Quarterly Earnings
Agenus (NASDAQ:AGEN) is set to give its latest quarterly earnings report on Mon...
11-08 04:05
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
UroGen Pharma reported Q3 2025 financial results, highlighting strong performance of ZUSDURI with $1.8M net revenue and a $4.5M demand estimate in October. JELMYTO contributed $25.7M revenue, up 13% YoY. UGN-103 showed a 77.8% complete response rate, aligning with ENVISION results, with FDA agreement on NDA submission. Cash reserves stood at $127.4M. A conference call was scheduled for further updates.
11-06 13:00
Orchestra BioMed Announces First Patient Enrollments In Virtue SAB In Treatment Of Coronary ISR Trial
Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus
10-27 21:04
【山证汽车】汽车智能驾驶专题（一）：智驾已是“必答题”，低阶配置平权与高阶功能落地共振
登录新浪财经APP 搜索【信披】查看更多考评等级 投资要点 近年来，智能已经是各家汽车企业的“必答题”，无论新能源、燃油车智能功能渗透率正在快...
10-22 08:45
Agenus Releases New Data From Its botensilimab And balstilimab Combination Showing Durable Survival Benefits Across Multiple Late-Stage, Treatment-Resistant Cancers And That ~40% Of Patients With Very Limited Survival Expectation Are Alive At Two Years
Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastasesSignals of tumor agnostic benefit observedTumor types included CRC, sarcoma, ovarian, NSCLC,
10-17 20:10
人工智能企业、网络大V、平台方与监管部门同台，V聚场内多方共话AI技术发展新未来
转自：上海杨浦 “每月在B站观看AI内容用户有1.4亿，95后用户占比80％以上……”“AIGC浪潮下内容创作的机遇与挑战在哪里？”10月10日下午，由上海市委...
10-12 11:05
